Read our news and press releases

As a business striving for growth, Halberd is rapidly changing. This means that we have many stories to tell, we like to share them with you.

Sep 27 2022

Halberd Enters Strategic Alliance for Longevity, Alzheimer’s Disease, and Cancer Early Detection, Prevention and Treatment

By |2022-09-26T21:24:04-04:00September 27th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: "HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”.  The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease ...

Aug 23 2022

Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein

By |2022-08-22T20:05:56-04:00August 23rd, 2022|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, August 23, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing.  PD-1 (programmed cell death–1) is a T-Cell protein which can be used by tumor cells to fool the body’s immune system into allowing the ...

Jul 14 2022

Halberd’s Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron

By |2022-07-13T20:33:40-04:00July 14th, 2022|Investor News, News, Press Releases|0 Comments

Boosts Effectiveness of Commercial Covid Antibodies by 45% Jackson Center, PA, July 14, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron.  When Halberd’s antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness ...

Jul 12 2022

Halberd Corporation Update, CEO Letter and 2022 Expectations

By |2022-07-11T19:19:34-04:00July 12th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Q2 Accomplishments and a Look to the Future Jackson Center, PA, July 12, 2022.  Halberd Corporation (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team.  The accomplishments for the Second Quarter ending June 30, 2022, are as follows: 2Q ACHIEVEMENTS Added an animal testing expert (DVM/PhD) ...

Jun 8 2022

Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

By |2022-06-07T21:21:57-04:00June 8th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, June 8, 2022 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd’s patented extracorporeal disease eradication processes.  Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi ...

May 18 2022

Halberd Engages Professional Firm to Proceed with FDA Filings

By |2022-05-17T18:30:32-04:00May 18th, 2022|Investor News, News, Press Releases|1 Comment

Jackson Center, PA, May 18, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug Administration’s (FDA) complex application and certification processes.  mdi will guide Halberd on the FDA application and testing protocol and assist in filing the appropriate documents ...

May 12 2022

Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB

By |2022-05-11T18:58:14-04:00May 12th, 2022|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, May 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange.  Once Halberd’s shares are qualified under the Securities Exchange Act of 1934 (the “34 ...

Apr 25 2022

Halberd CEO Letter

By |2022-04-24T18:20:33-04:00April 25th, 2022|Featured, Investor News, News, Press Releases, Update Letter|0 Comments

Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...

Apr 18 2022

Halberd Eliminates E. coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics

By |2022-04-17T19:16:30-04:00April 18th, 2022|Featured, Investor News, Medical, Press Releases|0 Comments

Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states.  The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes.  This ...

Apr 11 2022

Halberd Entering the Medical Metaverse(TM)

By |2022-04-10T18:42:06-04:00April 11th, 2022|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, April 11, 2022 – Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of nonfungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc. Halberd is currently in negotiations to engage a team of experts in ...

Go to Top